Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 10/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.52 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.51 |
| ▸ | CALCR | P30988 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | NPY4R | P50391 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reltecimod SCHEMBL29533665 | 0.95 | CXCL8 (0.52) | CXCL8NTSR1CALCRLNTSR2EPHA2 | |
| SCHEMBL30974464 | 0.86 | SLC6A2 (0.58) | NTSR1CALCRLNTSR2CALCR | |
| SCHEMBL13130786 | 0.86 | EPHA2 (0.59) | CXCL8CALCRLEPHA2 | |
| SCHEMBL30786569 | 0.84 | SLC6A2 (0.58) | CALCRLEPHA2 | |
| SCHEMBL38665591 | 0.84 | SLC6A2 (0.59) | CXCL8NTSR1CALCRLCALCR | |
| SCHEMBL31717953 | 0.84 | NTSR1 (0.56) | NTSR1NTSR2REN | |
| SCHEMBL32677399 | 0.83 | BACE1 (0.53) | NTSR1CALCRLNTSR2REN | |
| Almplyaci SCHEMBL29615870 | 0.83 | NTSR1 (0.57) | NTSR1NTSR2 | |
| SCHEMBL30116698 | 0.83 | CALCRL (0.59) | CXCL8CALCRLREN | |
| SCHEMBL30512680 | 0.83 | CXCL8 (0.54) | CXCL8NTSR1CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| WO-2025122988-A2 | ENGINEERED ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | Aarvik Therapeutics, Inc. (US) | 2025-06-12 | — | — | WO | claimed |
| US-12091719-B2 | Compositions and methods for detecting viruses in a sample | WASHINGTON UNIVERSITY (US) | 2024-09-17 | — | — | US | claimed |
| EP-4234138-B1 | MACHINING TOOL | LEDERMANN GMBH & CO KG (DE) | 2024-04-24 | — | — | EP | claimed |
| EP-4323073-A1 | PESTICIDAL MINICELLS AND COMPOSITIONS THEREOF FOR AGRICULTURAL APPLICATIONS | Invaio Sciences, Inc. (US) | 2024-02-21 | — | — | EP | claimed |
| EP-4234139-A1 | MACHINING TOOL | Ledermann GmbH & Co. KG (DE) | 2023-08-30 | — | — | EP | claimed |
| EP-4234138-A1 | MACHINING TOOL | Ledermann GmbH & Co. KG (DE) | 2023-08-30 | — | — | EP | claimed |
| CN-116282658-A | Oil removal equipment and method | 中国恩菲工程技术有限公司 | 2023-06-23 | — | — | CN | claimed |
| WO-2022221535-A1 | PESTICIDAL MINICELLS AND COMPOSITIONS THEREOF FOR AGRICULTURAL APPLICATIONS | INVAIO SCIENCES, INC. (US) | 2022-10-20 | — | — | WO | claimed |
| US-20260103535-A1 | HUMAN CD163 ANTIBODIES AND USES THEREOF | ONCORESPONSE INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260085125-A1 | APELIN RECEPTOR BINDING POLYPEPTIDES AND METHODS | TECTONIC OPERATING COMPANY INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4705484-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TAU-RELATED DISORDERS | Voyager Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260035448-A1 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | SCHOLAR ROCK INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260001946-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORIGINATING FROM THE ENDODERM | BT BIDCO INC (US) | 2026-01-01 | — | — | US | disclosed |
| CN-114423787-A | Immunomodulatory antibodies and methods of use thereof | 昂科里斯庞斯公司 | 2022-04-29 | — | — | CN | disclosed |
| US-11304989-B2 | Peptides for use in the treatment of viral infections | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2022-04-19 | — | — | US | disclosed |
| CN-114262402-A | Preparation method of macroporous adsorption resin for caramel decolorization | 江苏金杉新材料有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-20220073619-A1 | BTN3A BINDING PROTEINS AND USES THEREOF | IMCHECK THERAPEUTICS (FR) | 2022-03-10 | — | — | US | disclosed |
| US-20220072016-A1 | MILTEFOSINE FOR THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 | PROFOUNDA HEALTH AND BEAUTY INC. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103535-A1 | HUMAN CD163 ANTIBODIES AND USES THEREOF | SLC11A2, ARG1, FCGR3B | CXCL8 1700/4885NTSR1 2255/4885CALCRL 193/4885 |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | S100A8, TP53, AQP1 | CXCL8 7/4885NTSR1 3370/4885CALCRL 1959/4885 |
| US-20220072016-A1 | MILTEFOSINE FOR THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 | ACE, ACE2, BDKRB2 | CXCL8 9/4885NTSR1 260/4885CALCRL 222/4885 |
| US-20260001946-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORIGINATING FROM THE ENDODERM | IL2, IL18, TSLP | CXCL8 8/4885NTSR1 2106/4885CALCRL 489/4885 |
| US-20260085125-A1 | APELIN RECEPTOR BINDING POLYPEPTIDES AND METHODS | APLNR, ACVRL1, EDNRA | CXCL8 2021/4885NTSR1 17/4885CALCRL 28/4885 |
| US-20260035448-A1 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | IGF2BP2, MYO1G, IGF2BP1 | CXCL8 3929/4885NTSR1 555/4885CALCRL 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.